Ovarian Cancer: Understanding Modern Treatment Options and Available Medicines 

Ovarian cancer is classified as one of the complex gynaecological cancers. It is not difficult because it can be treated with medication, but rather because of the fact that it is diagnosed at an advanced stage. The treatment and processes have changed a lot over the last decade, including the application of targeted treatment and genetic testing. 

Key Takeaways 

• Most ovarian cancers are diagnosed at stage III or IV, making combination treatment with surgery and chemotherapy the starting point for most patients. 

• Genetic testing for BRCA1 and BRCA2 mutations is now a standard part of ovarian cancer care and directly influences which targeted therapies are appropriate. 

• PARP inhibitors have transformed maintenance therapy for BRCA-mutated ovarian cancer and significantly extended progression-free survival. 

• Understanding the treatment options available and what each involves helps patients engage more actively in decisions about their care.

What Ovarian Cancer Is and Why It Remains Challenging 

The most frequent cause of ovarian cancer is the fallopian tube or peritoneal surface because the ovaries are involved only after the initial development. The most common histology type of ovarian cancer is high-grade serous ovarian carcinoma, which makes up about 70 per cent of cases, and it is the type of ovarian cancer most often related to BRCA mutations and the most sensitive to platinum-based chemotherapy treatment. 

The problem with the disease is that it lacks warning signs and usually becomes detected after spreading widely; some common signs, such as bloating, abdominal pain, and frequent urination, can be mistakenly interpreted as less important. 

How Ovarian Cancer Is Assessed Before Treatment Begins 

A proper diagnosis of ovarian cancer needs various imaging techniques, some tumour markers and a tissue confirmation. By using transvaginal ultrasound and CT for the chest, abdomen and pelvis, doctors can determine how the cancer has spread. Usually, CA-125 is the marker used for this, but it is not sufficient. Only histopathology of the obtained samples can tell physicians what type and grade of the tumour the patient has. MRI provides surgeons with the necessary information for better surgical planning, while PSMA or PET imaging may be used in some cases. In addition, tests for BRCA1 and BRCA2 mutations, as well as tests determining the homologous recombination deficiency status of the tumour, are now part of the standard process of diagnosing ovarian cancer. 

Surgery and Chemotherapy: The Treatment Foundation 

Cytoreductive surgery remains the main treatment for advanced ovarian cancer in newly diagnosed patients since the main aim is the removal of the maximal tumour amount and is followed by platinum-based chemotherapy. The current international gold standard in terms of the combination of carboplatin and paclitaxel is six cycles of carbo/taxol base chemotherapy after surgery. Tumour resectability or absence of residual disease is one of the best prognostic factors for long-term outcome, making surgical skills highly important in treatment. 

The Role of PARP Inhibitors in Maintenance Therapy 

The use of these inhibitors as part of maintenance therapy following response to platinum chemotherapy is now standard practice in patients with BRCA mutations and homologous recombination deficiencies. These inhibitors inhibit the enzyme poly ADP-ribose polymerase, which is essential for the survival of BRCA-deficient cancer cells for DNA damage repair. Thus, inhibiting PARP in a cell that already cannot repair through BRCA will result in accumulation of irreparable DNA breaks, leading to cell death, a phenomenon characterised as synthetic lethality. 

Olaparib and Its Clinical Role 

OLAPARIB is the first PARP inhibitor to receive regulatory approval for ovarian cancer and remains one of the most comprehensively studied agents in this class. The SOLO-1 trial demonstrated that maintenance olaparib reduced the risk of disease progression or death by 70 per cent in newly diagnosed BRCA-mutated advanced ovarian cancer patients who had responded to first-line platinum chemotherapy. 

Lynparza 150mg Tablet is a formulation of olaparib prescribed as maintenance therapy following a complete or partial response to first-line or subsequent platinum-based chemotherapy in patients with BRCA1 or BRCA2 mutations. It is taken orally twice daily as two 150mg tablets, and the treatment continues until disease progression or unacceptable toxicity. It is prescribed and monitored by a gynaecological oncologist. 

Bevacizumab in Combination Treatment 

For individuals suffering from advanced ovarian cancer and lacking BRCA mutations or whose tumours show homologous recombination proficiency, treatment with bevacizumab can be a valid choice. The anti-angiogenic medication works by preventing the creation of new blood vessels that cancer requires for its growth. It has been authorised for use with chemotherapy and as maintenance treatment after chemotherapy is finished, and studies have shown that it improves progression-free survival rates significantly in phase III studies. 

Managing Side Effects During Treatment 

The side effect profiles of the different ovarian cancer treatment modalities vary significantly: 

• Platinum-based chemotherapy commonly causes nausea, fatigue, peripheral neuropathy, and bone marrow suppression requiring blood count monitoring 

• Paclitaxel causes hair loss and can worsen neuropathy symptoms 

• Olaparib frequently causes nausea, fatigue, and anaemia, with nausea most prominent in the early weeks of treatment 

• Bevacizumab carries risks of hypertension, wound healing complications, and rarely bowel fistula formation 

Most side effects are manageable with supportive medications and dose modifications where needed. Patients should communicate any new or worsening symptoms to their oncology team promptly. 

Emotional and Mental Health During Treatment 

The emotional burden of an advanced ovarian cancer diagnosis is heavy and made worse because it often comes after months of vague symptoms. The diagnosis raises the questions of fertility concerns in younger women, the effect of treatment on everyday life, fear of recurrence, and an unknown future. Gynecologic Oncology centres with trained cancer nurse navigators, social workers, and cancer peer support programs provide compassionate support along with the medical treatment process. 

Importance of Follow-Up Care 

To assess response to therapy, CA-125 levels are measured, and the patient is examined periodically after therapy begins. Imaging is done when cancer marker levels are higher in the blood, or when alarm signals of the new tumour are present. The issue of genetic consulting for female relatives of patients with BRCA mutations has gained greater importance since the close female relatives are allowed to use the tools to reduce the risk.  

What Is Worth Remembering 

The improvement of treatment of ovarian cancer has occurred due to the start of targeted treatment methods five years back. With the availability of genetic testing and PARP inhibitors, maintenance therapy has changed the long-term management of this disease. Understanding the philosophy of the treatment methods and the duties performed at each stage of the therapy allows women to become active participants in the process.  

Disclaimer: This article is for general informational purposes only and should not be considered medical advice. Always consult a qualified gynaecological oncologist for diagnosis, treatment planning, and guidance specific to your condition.